Clinical trials recruiting for Locally Advanced Breast Cancer
13
Recruiting trials
34
US states with sites
25
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 5 |
| North Carolina | 4 |
| California | 3 |
| Colorado | 3 |
| Florida | 3 |
| Minnesota | 3 |
| Tennessee | 3 |
| Texas | 3 |
| Washington | 3 |
| Arizona | 2 |
| Connecticut | 2 |
| Georgia | 2 |
Top cities
New York, New York 4Aurora, Colorado 3Houston, Texas 3Minneapolis, Minnesota 3Nashville, Tennessee 3San Francisco, California 3Charlotte, North Carolina 2Columbus, Ohio 2La Jolla, California 2New Haven, Connecticut 2
Self-screener
Recruiting trials
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
- A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
- A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
- Breast Cancer Exercise Intervention Study
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
- Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
Related conditions
Trials recruiting for Locally Advanced Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Metastatic breast cancer 131HER2-positive breast cancer 75HER2-negative Breast Cancer 57Early-stage Breast Cancer 27Triple-negative breast cancer 138TNBC - Triple-Negative Breast Cancer 35Hormone Receptor Positive Tumor 10ER Positive Breast Cancer 12Breast Tumors 4
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Locally Advanced Breast Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.